Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel

Abstract Background There are no head-to-head clinical studies comparing chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed or refractory aggressive large B-cell lymphomas. Naive, indirect comparisons may be inappropriate, as the study designs and patient populations coul...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Guillaume Cartron, Christopher P. Fox, Fei Fei Liu, Ana Kostic, Jens Hasskarl, Daniel Li, Ashley Bonner, Yixie Zhang, David G. Maloney, John Kuruvilla
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2022-03-01
Schriftenreihe:	Experimental Hematology & Oncology
Schlagworte:	CAR T-cell therapy Lisocabtagene maraleucel Tisagenlecleucel Indirect treatment comparison Matching-adjusted indirect comparison
Online-Zugang:	https://doi.org/10.1186/s40164-022-00268-z
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!